New data on firazyr for kids with HAE: safe and effective?
NCT ID NCT05509569
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study looked at the safety and effectiveness of Firazyr (icatibant) for treating sudden swelling attacks in children (ages 2-17) with hereditary angioedema (HAE). Researchers tracked side effects and how quickly symptoms improved after the injection. The study involved 32 children in Japan and followed standard care practices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda selected site
Tokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.